Somewhat Positive Media Coverage Somewhat Unlikely to Impact Repligen (RGEN) Stock Price
News articles about Repligen (NASDAQ:RGEN) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Repligen earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.3538654342923 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. BidaskClub lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Jefferies Group restated a “hold” rating and issued a $40.00 price target on shares of Repligen in a research note on Thursday, October 19th. CL King assumed coverage on shares of Repligen in a research note on Monday, November 13th. They issued a “buy” rating and a $41.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Repligen in a research note on Friday, December 8th. They issued a “buy” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $44.38.
Shares of Repligen (NASDAQ RGEN) traded down $0.77 during trading hours on Thursday, hitting $31.89. 120,075 shares of the company’s stock traded hands, compared to its average volume of 227,098. Repligen has a 12 month low of $29.09 and a 12 month high of $46.81. The firm has a market capitalization of $1,432.43, a price-to-earnings ratio of 53.95, a P/E/G ratio of 1.84 and a beta of 0.91.
In related news, CEO Anthony Hunt sold 8,970 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $35.95, for a total transaction of $322,471.50. Following the transaction, the chief executive officer now owns 83,613 shares in the company, valued at $3,005,887.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Howard Benjamin sold 12,729 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the transaction, the vice president now owns 36,554 shares in the company, valued at approximately $1,291,818.36. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Repligen (RGEN) Stock Price” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-repligen-rgen-stock-price/1852830.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.